Columbia Care LLC. has announced this morning that the company has gain approval from Malta Enterprises, the regulatory economic development agency in the country, to receive licenses within the country to import, export, cultivate, process, and distribute medicinal cannabis.
The company’s branded product lines such as ClaraCeed™, TheraCeed™ and EleCeed™ are consisted of proprietary pharmaceutical-quality medical cannabis derived products. . Colombia Care is expected to operate out of a GMP-certified and ISO-certified research and manufacturing facilityin Malta as well.
Columbia Care is a private company located in the United states. Currently, the company is a large-scale producer and manufacturer of medicinal cannabis products and owns a network of over 750,000 patients. Their company is now planning to take their proven concept to countries around the world, with Europe being its first target.
Nicholas Vita, Chief Executive Officer of Columbia Care gave this statement in the press release, “….we have become the global leader from our base in the U.S., raising the bar for expectations, performance and industry standards. With a desire to realize our mission regardless of geography, we look forward to disrupting the status quo outside the U.S. and bringing our expertise to the rest of the world.”
You may be interested
Global Hemp Group Announces Harvest Update on their CBD Hemp Farm in Scio OregonEditor - November 27, 2018
Vancouver, BC -- (November 27, 2018) -- GLOBAL HEMP GROUP INC. (“GHG” or the “Company”) (CSE: GHG / OTC: GBHPF / FRANKFURT: GHG) and its joint venture…
Wayland Group Enters UK Cannabis Market with Theros Pharma AcquisitionEditor - November 26, 2018
Wayland Group (CSE:WAYL) (OTCQB:MRRCF) has announced this morning that their company has entered into an agreement to acquire 51% of UK company Theros Pharma Ltd. The Wayland Group…
GW Pharma’s CBD Pharmaceutical, Epidiolex, Shows Results in Lowering Seizures in Clinical TrialsEditor - November 26, 2018
GW Pharmaceuticals (Nasdaq: GWPH) has announced this morning that their company has completed a double-blind, placebo-controlled Phase 3 clinical trial for its Cannabidiol (CBD) derived product EPIDIOLEX®.…